F. Stephen Hodi, MD
Year elected: 2012
Current membership category: Active
Dana-Farber Cancer Institute
450 Brookline Avenue
D540c
Boston, MA 02215
United States of America
Phone: 6176325053
Facsimile: 6175827992
Email: Stephen_hodi@dfci.harvard.edu

Biographical statement

Dr. Hodi has pioneered advancements in the treatments for melanoma. He was the first to report the clinical use of CTLA-4 blocking antibodies in patients. The work included defining mechanisms of action of CTLA-4 blockade and led to the seminal study that revealed for the first time a survival advantage for patients and the basis for FDA approval. In addition, Dr. Hodi demonstrated the first successful use of a tyrosine-kinase inhibitor against KIT in melanoma, confirming the principle that melanoma may be treated based on the mutational status of patient’s tumor.

Institutional affiliations

Harvard Medical School, Dana-Farber Cancer Institute (Primary)
William C. Hahn, MD, PhD is the representative at this institution.

Specialties

Internal Medicine